This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
1. Patients aged ≥18 years old
2. Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL [International Workshop on Chronic Lymphocytic Leukemia] criteria)；
3. Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on Zanubrutinib;
4.Prior or current use of Zanubrutinib for ≥3 months
None
Investigators participating in this observational study should include all patients with CLL who initiated treatment with zanubrutinib over the period from July 1st, 2020 to the present, regardless of the treatment status at the time of inclusion. Thus, at the time of enrolment and retrospective data collection, patients may still be on treatment or have stopped treatment for any reason.
Cohort
Retrospective
Zanubrutinib
Drugpatients with treatment naive or R/R CLL who treatment with Zanubrutinib
Progression Free Survival (PFS)
PFS is defined as the duration from date of Zanubrutinib initiation to date of disease progression (PD \[according to the physician's evaluation\]) or death from any cause
Overall Survival
OS is defined as the time from the starting date of Zanubrutinib to the date of death due to any cause.
Time to Next Therapy (TTNT)
The TTNT will be calculated as the difference between Zanubrutinib initiation date and initiation date of the first next therapy for CLL
Adverse Events
Percentage of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Special Situations
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
